German biotech company BioNTech plans to scale down cell therapy production at its first US plant because its CAR-T candidate fell short of expectations in early cancer trials. At the end of this summer, BioNTech's cell therapy plant in Gaithersburg, Maryland will lay off 63 employees, mainly involving the cell therapy technology operations team at the site.

German biotech company BioNTech plans to scale down cell therapy production at its first US plant because its CAR-T candidate fell short of expectations in early cancer trials. At the end of this summer, BioNTech's cell therapy plant in Gaithersburg, Maryland will lay off 63 employees, mainly involving the cell therapy technology operations team at the site.